**11.** Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385:2485-91.
**12.** Arangalage D, Cimadevilla C, Alkhoder S, et al. Agreement between the new EuroSCORE II, the logistic EuroSCORE and the Society of Thoracic Surgeons score: implications for transcatheter aortic valve implantation. Arch Cardiovasc, DiS. 2014;107:353-60.
**13.** Durand E, Borz B, Godin MP, et al. Performance analysis of EuroSCORE II compared to the original logistic EuroSCORE and STS scores for predicting 30-day mortality after transcatheter aortic valve replacement. Am J Cardiol. 2013;111:891-7.
**14.** Arnold SV, Afilalo J, Spertus JA, et al. U.S. CoreValve Investigators. Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016;68:1868-77.
**15.** Lindman BR, Alexander KP, O'Gara PT, et al. Futility, benefit, and transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014 Jul;7(7):707-16. doi: 10.1016/j.jcin.2014. 01. 167. Epub 2014 Jun 18. PMID: 24954571; PMCID: PMC4322002.
**16.** Kulminski A, Yashin A, Arbeev K, et al. Cumulative index of health disorders as an indicator of aging–associated processes in the elderly: Results from analyses of the National Long Term Care Survey. Mech Ageing Dev. 2007;128:250-258.
**17.** Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-156.
**18.** Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62 A:722-727.
**19.** Rodes-Cabau J, Webb JG, Cheung A, et al. Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol. 2012;60:1864-75.
**20.** Anand A, Harley C, Visvanathan A, et al. The relationship between preoperative frailty and outcomes following transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2017;3:123-32.
**21.** Vahanian A, Bayersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart. 2022 Feb 12;43(7):561-632.
**22.** Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb 2;143(5):e72-e227. doi: 10.1161/CIR.0000000000000923. Epub 2020 Dec 17. Erratum in: Circulation. 2021 Feb 2;143(5):e229. Erratum in: Circulation. 2023 Aug 22;148(8):e8. PMID: 33332150.
**23.** Abellan van Kan G, Rolland Y, Andrieu S, et al. Gait speed at ususal pace as a predictor of adverse outcomes in community dwelling older people. An International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009;13:88-88.
**24.** Afilalo J, Eisenberg MJ, Morin JF, et al. Gait speed as an incremental predictor of mortality and major morbidity in elderly patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56:1668-1676.
**25.** Arnold SV, Reynolds MR, Lei Y, et al. Predictors of poor outcomes after transcatheter aortic valve replacement results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation. 2014; 129:2682-90.
**26.** Eichler S, Salzwedel A, Harnath A, et al. Nutrition and mobility predict all-cause mortality in patients 12 months after transcatheter aortic valve implantation. Clin Res Cardiol. 2018;107:304-11.
**27.** Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793-6.
**28.** Schoenenberger AW, Stortecky S, Neumann S, et al. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J. 2013;34:684-92.
**29.** Yamamoto M, Mouillet G, Oguri A, et al. Effect of body mass index on 30- and 365-day complication and survival rates of transcatheter aortic valve implantation (from the FRench Aortic National CoreValve and Edwards 2 [FRANCE 2] registry). Am J Cardiol. 2013;112:1932-7.
**30.** Mamane S, Mullie L, Lok Ok Choo W, et al. Sarcopenia in older adults undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2019;74:3178-80.
**31.**Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol. 2017;70:689-700.
**32.** Mack MJ, Stoler R. Intervention for Aortic Stenosis: The Measurement of Frailty Matters. J Am Coll Cardiol. 2017;70: 701-3.
**33.** Patel KP, Treibel TA, Scully PR, et al. Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity. Interv Cardiol. 2022 Jan 18;17:e01. doi: 10.15420/icr.2021. 15. PMID: 35111240; PMCID: PMC8790725.
**34.** Puri R, Iung B, Cohen DJ, et al. TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. Eur Heart J. 2016 Jul 21;37(28):2217-25. doi: 10.1093/eurheartj/ehv756. Epub 2016 Jan 26. PMID: 26819226.
**35.** Yamamoto M, Hayashida K, Mouillet G, et al. Prognostic value of chronic kidney disease after transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;62:869-877.
**36.** Dumonteil N, van der Boon RM, Tchetche D, et. al. Impact of preoperative chronic kidney disease on shortand long-term outcomes after transcatheter aortic valve implantation: a Pooled-Rotterdam-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. Am Heart J. 2013;165:752-760.
**37.** Ferro CJ, Chue CD, Belder MA De, et al. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart. 2015;101:546-52.
**38.** Schymik G, Bramlage P, Herzberger V, et al. Impact of dialysis on the prognosis of patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2019;123:315-22.
**39.** Rheude T, Pellegrini C, Michel J, et al. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. Int J Cardiol. 2017;244:93-9.
**40.** Mangner N, Woitek FJ, Haussig S, et al. Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement. J Interv Cardiol. 2018;31:188-96.
**41.** Watanabe Y, Kozuma K, Hioki H, et al. Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer. Am J Cardiol. 2016;118:572-7.
**42.** Tamburino C, Capodanno D, Ramondo A, et. al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011;123:299-308.
**43.** Urena M, Webb JG, Eltchaninoff H, et. al Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death, J Am Coll Cardiol. 2015;65:437-448.
**44.** Elmariah S, Palacios IF, McAndrew T, et al. Outcomes of transcatheter and surgical aortic valve replacement in high risk patients with aortic stenosis and left ventricular dysfunction: results from the Placement of Aortic Transcatheter Valves (PARTNER) trial (cohort A). Circ Cardiovasc Interv. 2013;6:604-14.
**45.** Le Ven, Freeman M, Webb J, et. al. Impact of low flow on the outcome of high-risk patients undergoing transcatheter aortic valve -replacement. J Am Coll Cardiol. 2013;62:782-788.
**46.** Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759-67.
**47.** Nombela-Franco L, Ribeiro HB, Urena M et.al. Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. J Am Coll Cardiol. 2014;63:2643-2658.
**48.** Muratori M, Fusini L, Tamborini G, et al. Mitral valve regurgitation in patients undergoing TAVI: impact of severity and etiology on clinical outcome. Int J Cardiol. 2020 Jan 15;299:228-234.
**49.** Sannino A, Gargiulo G, Schiattarella GG, et al. A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2016;12:e1047-56.
**50.** Sinning JM, Hammerstingl C, Chin D, et al. Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. EuroIntervention. 2014;9:1042-9.
**51.** Asami M, Stortecky S, Praz F, et al. Prognostic value of right ventricular dysfunction on clinical outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Imaging. 2019;12:577-87.
**52.** Paradis JM, Labbe B, Rodes-Cabau J, et al. Coronary artery disease and transcatheter aortic valve replacement: Current treatment paradigms. Coron. Artery, DiS. 2015;26:272-278.
**53.** Dewey TM, Brown DL, Herbert MA, et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg. 2010 Mar;89(3):758-67; discussion 767. doi: 10.1016/j.athoracsur.2009. 12. 033. PMID: 20172123.
**54.** Stefanini GG, Stortecky S, Cao D, et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J. 2014 Oct 1;35(37):2530-40. doi: 10.1093/eurheartj/ehu074. Epub 2014 Mar 28. PMID: 24682843.
**55.** Altibi AM, Ghanem F, Hammad F, et al. Clinical Outcomes of Revascularization with Percutaneous Coronary Intervention Prior to Transcatheter Aortic Valve Replacement: A Comprehensive Meta-Analysis. Curr Probl Cardiol. 2022 Nov;47(11):101339. doi: 10.1016/j.cpcardiol.2022.101339. Epub 2022 Jul 29. PMID: 35908687.
**56.** Patterson T, Clayton T, Dodd M, et al. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A Randomized Clinical Trial. JACC Cardiovasc. Interv. 2021;14:1965-1974.
**57.** Sherwood MW, Xiang, K, Matsouaka R, et al. Incidence, temporal trends, and associated outcomes of vascular and bleeding complications in patients undergoing transfemoral transcatheter aortic valve replacement: Insights from the society of thoracic Surgeons/American college of cardiology transcatheter valve therapies registry. Circ. Cardiovasc. Interv. 2020;13:e8227.
**58.** Francone M, Budde R, Bremerich J, et al. CT and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting — a consensus document by the European Society of Cardiovascular Radiology (ESCR). Eur Radiol. 2020;30(5):2627-2650.